Patent intelligence · US
US 9988603
Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
Patent details — US 9988603
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 5, 2018
- Expiration
- May 31, 2038
- Claims
- 17
- CPC classes
- A61P, A61P7/04, A61P7/08
Quick answer
US 9988603 (Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions) is held by Stem Cell & Regenerative Medicine International. Status: granted. Granted Jun 5, 2018. Expires May 31, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61P, A61P7/04, A61P7/08
More from Stem Cell & Regenerative Medicine International
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9988603?
US 9988603 (Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions) is held by Stem Cell & Regenerative Medicine International. Status: granted. Granted Jun 5, 2018. Expires May 31, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9988603?
Stem Cell & Regenerative Medicine International is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9988603 expire?
Our index shows an expiration date of May 31, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.